Shenzhen - Delayed Quote CNY

Tus-Pharmaceutical Group Co., Ltd. (000590.SZ)

6.56 +0.15 (+2.34%)
At close: 2:53 PM GMT+8
Loading Chart for 000590.SZ
DELL
  • Previous Close 6.41
  • Open 6.24
  • Bid 6.55 x --
  • Ask 6.56 x --
  • Day's Range 6.32 - 6.57
  • 52 Week Range 4.80 - 11.25
  • Volume 4,575,300
  • Avg. Volume 9,070,957
  • Market Cap (intraday) 1.571B
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) 59.64
  • EPS (TTM) 0.11
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jun 21, 2013
  • 1y Target Est --

Tus-Pharmaceutical Group Co., Ltd. manufactures and sells Chinese patent medicines, chemical medicines, and health foods in China. The company offers Guhan health essences, Danzao oral liquids, Danhuang granules, and Yangxin Dingpalan granules. It also provides tonic health care, cardiovascular and cerebrovascular products, children's nutrition, cold products, heat-clearing, and detoxification products, etc. The company was formerly known as Tus-Guhan Group Corp.,Ltd. Tus-Pharmaceutical Group Co., Ltd. was founded in 1956 and is headquartered in Hengyang, China.

www.tuspharma.cn

1,237

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 000590.SZ

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

000590.SZ
26.79%
SSE Composite Index
2.62%

1-Year Return

000590.SZ
22.37%
SSE Composite Index
6.79%

3-Year Return

000590.SZ
18.31%
SSE Composite Index
12.13%

5-Year Return

000590.SZ
58.51%
SSE Composite Index
4.65%

Compare To: 000590.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 000590.SZ

Valuation Measures

Annual
As of 4/24/2024
  • Market Cap

    1.54B

  • Enterprise Value

    1.44B

  • Trailing P/E

    60.82

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.79

  • Price/Book (mrq)

    2.12

  • Enterprise Value/Revenue

    3.56

  • Enterprise Value/EBITDA

    23.17

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.24%

  • Return on Assets (ttm)

    0.77%

  • Return on Equity (ttm)

    3.48%

  • Revenue (ttm)

    404.65M

  • Net Income Avi to Common (ttm)

    25.25M

  • Diluted EPS (ttm)

    0.11

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    189.77M

  • Total Debt/Equity (mrq)

    13.10%

  • Levered Free Cash Flow (ttm)

    -64.34M

Company Insights: 000590.SZ

People Also Watch